MX2015015115A - Metodos de tratamiento de cancer. - Google Patents
Metodos de tratamiento de cancer.Info
- Publication number
- MX2015015115A MX2015015115A MX2015015115A MX2015015115A MX2015015115A MX 2015015115 A MX2015015115 A MX 2015015115A MX 2015015115 A MX2015015115 A MX 2015015115A MX 2015015115 A MX2015015115 A MX 2015015115A MX 2015015115 A MX2015015115 A MX 2015015115A
- Authority
- MX
- Mexico
- Prior art keywords
- fgfr1
- methods
- overexpression
- ecd
- fusion molecule
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 abstract 9
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 abstract 9
- 230000004927 fusion Effects 0.000 abstract 3
- 230000002018 overexpression Effects 0.000 abstract 3
- 230000004544 DNA amplification Effects 0.000 abstract 2
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 abstract 2
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 abstract 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 abstract 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 abstract 2
- 230000003321 amplification Effects 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 238000003199 nucleic acid amplification method Methods 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361818220P | 2013-05-01 | 2013-05-01 | |
| US201361831029P | 2013-06-04 | 2013-06-04 | |
| PCT/US2014/036140 WO2014179448A2 (en) | 2013-05-01 | 2014-04-30 | Methods of treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2015015115A true MX2015015115A (es) | 2016-06-07 |
Family
ID=50928263
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2015015115A MX2015015115A (es) | 2013-05-01 | 2014-04-30 | Metodos de tratamiento de cancer. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20160067307A1 (https=) |
| EP (1) | EP2991669A2 (https=) |
| JP (1) | JP2016526016A (https=) |
| KR (1) | KR20160003141A (https=) |
| CN (1) | CN105188732A (https=) |
| AU (1) | AU2014259956A1 (https=) |
| BR (1) | BR112015027607A8 (https=) |
| CA (1) | CA2908391A1 (https=) |
| HK (1) | HK1213817A1 (https=) |
| MX (1) | MX2015015115A (https=) |
| RU (1) | RU2015150233A (https=) |
| SG (1) | SG11201508878WA (https=) |
| WO (1) | WO2014179448A2 (https=) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| US8481038B2 (en) | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| CN107823630A (zh) | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
| KR102516152B1 (ko) | 2013-08-01 | 2023-03-31 | 파이브 프라임 테라퓨틱스, 인크. | 비푸코실화된 항-ｆｇｆｒ２ｉｉｉｂ 항체 |
| BR112018001438A2 (en) * | 2015-07-24 | 2018-12-04 | Debiopharm International S.A. | gffr expression and susceptibility to a gffr inhibitor |
| MX2018006181A (es) * | 2015-11-23 | 2018-09-24 | Five Prime Therapeutics Inc | Inhibidores de fgfr2 solos o en combinacion con agentes que estimulan el sistema inmunitario en el tratamiento contra el cancer. |
| PL238516B1 (pl) | 2016-06-13 | 2021-08-30 | Univ Wroclawski | Sposób otrzymywania modyfikowanego polipeptydu |
| SG11201906249PA (en) * | 2017-02-06 | 2019-08-27 | Rainier Therapeutics Inc | Methods, compositions, and kits for treatment of cancer |
| WO2018195273A1 (en) * | 2017-04-19 | 2018-10-25 | The Corporation Of Mercer University | Sam-1 protein, composition and methods of use |
| PT3624837T (pt) | 2017-05-16 | 2025-10-01 | Five Prime Therapeutics Inc | Anticorpos anti-fgfr2 em combinação com agentes quimioterapêuticos no tratamento do cancro |
| EP3915576A1 (en) * | 2020-05-28 | 2021-12-01 | Fundació Privada Institut d'Investigació Oncològica de Vall-Hebron | Chimeric antigen receptors specific for p95her2 and uses thereof |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4318980A (en) | 1978-04-10 | 1982-03-09 | Miles Laboratories, Inc. | Heterogenous specific binding assay employing a cycling reactant as label |
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| US5700637A (en) | 1988-05-03 | 1997-12-23 | Isis Innovation Limited | Apparatus and method for analyzing polynucleotide sequences and method of generating oligonucleotide arrays |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5143854A (en) | 1989-06-07 | 1992-09-01 | Affymax Technologies N.V. | Large scale photolithographic solid phase synthesis of polypeptides and receptor binding screening thereof |
| US6552170B1 (en) | 1990-04-06 | 2003-04-22 | Amgen Inc. | PEGylation reagents and compounds formed therewith |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| ATE240740T1 (de) | 1991-03-15 | 2003-06-15 | Amgen Inc | Pegylation von polypeptiden |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| ZA9811162B (en) | 1997-12-12 | 2000-06-07 | Genentech Inc | Treatment with anti-ERBB2 antibodies. |
| US6573043B1 (en) | 1998-10-07 | 2003-06-03 | Genentech, Inc. | Tissue analysis and kits therefor |
| CA2348292A1 (en) | 1998-10-30 | 2000-05-11 | Takeda Chemical Industries, Ltd. | Betacellulin protein-containing preparation |
| WO2001075166A2 (en) | 2000-03-31 | 2001-10-11 | Genentech, Inc. | Compositions and methods for detecting and quantifying gene expression |
| CA2407556C (en) | 2000-05-19 | 2011-06-21 | Genentech, Inc. | Gene detection assay for improving the likelihood of an effective response to an erbb antagonist cancer therapy |
| US20050209310A1 (en) * | 2000-12-22 | 2005-09-22 | Chaplin David J | Methods for modulating tumor growth and metastasis |
| US6900292B2 (en) | 2001-08-17 | 2005-05-31 | Lee-Hwei K. Sun | Fc fusion proteins of human erythropoietin with increased biological activities |
| DK1638941T3 (da) | 2003-05-22 | 2010-10-11 | Abbott Lab | Indazol-, benzisoxazol- og benzisothiazolkinaseinhibitorer |
| WO2006076288A2 (en) | 2005-01-11 | 2006-07-20 | Five Prime Therapeutics, Inc. | Dna constructs for long-term expression of intravascularly injected naked dna |
| EP2083081A1 (en) | 2005-07-22 | 2009-07-29 | Five Prime Therapeutics, Inc. | Compositions and methods of treating disease with FGFR fusion proteins |
| JP2009514879A (ja) * | 2005-11-04 | 2009-04-09 | メルク エンド カムパニー インコーポレーテッド | Ｓａｈａ、カルボプラチン及びパクリタキセルを用いて癌を治療する方法及びその他の併用療法 |
| ES2342646B1 (es) | 2008-06-02 | 2011-04-26 | Institut De Recerca Hospital Universitari Vall Hebron | Metodo de diagnostico de canceres que expresan el receptor her-2 o sus variantes truncadas. |
| KR101910779B1 (ko) * | 2010-11-15 | 2018-10-22 | 파이브 프라임 테라퓨틱스, 인크. | Ｆｇｆｒ１ 세포밖 도메인 조합치료 |
| US8481038B2 (en) * | 2010-11-15 | 2013-07-09 | Five Prime Therapeutics, Inc. | Treatment of cancer with elevated dosages of soluble FGFR1 fusion proteins |
| US8951972B2 (en) * | 2010-12-09 | 2015-02-10 | Five Prime Therapeutics, Inc. | FGFR1 extracellular domain combination therapies for lung cancer |
| CN107823630A (zh) * | 2011-11-14 | 2018-03-23 | 戊瑞治疗有限公司 | 治疗癌症的方法 |
-
2014
- 2014-04-30 US US14/785,691 patent/US20160067307A1/en not_active Abandoned
- 2014-04-30 SG SG11201508878WA patent/SG11201508878WA/en unknown
- 2014-04-30 KR KR1020157033756A patent/KR20160003141A/ko not_active Withdrawn
- 2014-04-30 BR BR112015027607A patent/BR112015027607A8/pt not_active IP Right Cessation
- 2014-04-30 RU RU2015150233A patent/RU2015150233A/ru not_active Application Discontinuation
- 2014-04-30 JP JP2016512011A patent/JP2016526016A/ja active Pending
- 2014-04-30 EP EP14729530.7A patent/EP2991669A2/en not_active Withdrawn
- 2014-04-30 HK HK16101949.2A patent/HK1213817A1/zh unknown
- 2014-04-30 CA CA2908391A patent/CA2908391A1/en not_active Abandoned
- 2014-04-30 AU AU2014259956A patent/AU2014259956A1/en not_active Abandoned
- 2014-04-30 WO PCT/US2014/036140 patent/WO2014179448A2/en not_active Ceased
- 2014-04-30 MX MX2015015115A patent/MX2015015115A/es unknown
- 2014-04-30 CN CN201480024106.3A patent/CN105188732A/zh active Pending
-
2018
- 2018-01-03 US US15/861,047 patent/US20180280470A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112015027607A8 (pt) | 2018-01-23 |
| CN105188732A (zh) | 2015-12-23 |
| SG11201508878WA (en) | 2015-11-27 |
| WO2014179448A2 (en) | 2014-11-06 |
| HK1213817A1 (zh) | 2016-07-15 |
| EP2991669A2 (en) | 2016-03-09 |
| US20180280470A1 (en) | 2018-10-04 |
| BR112015027607A2 (pt) | 2017-12-05 |
| US20160067307A1 (en) | 2016-03-10 |
| KR20160003141A (ko) | 2016-01-08 |
| JP2016526016A (ja) | 2016-09-01 |
| CA2908391A1 (en) | 2014-11-06 |
| WO2014179448A3 (en) | 2014-12-24 |
| RU2015150233A (ru) | 2017-06-02 |
| AU2014259956A1 (en) | 2015-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2015015115A (es) | Metodos de tratamiento de cancer. | |
| HK1201462A1 (en) | Methods of treating cancer | |
| MX2024000614A (es) | Anticuerpos anti-fgfr2 combinados con quimioterapia para el tratamiento del cancer. | |
| AU2018201942B2 (en) | Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan | |
| WO2019236567A8 (en) | Tumor microenvironment-activated drug-binder conjugates, and uses related thereto | |
| CL2008003846A1 (es) | Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata. | |
| AU2018265888A1 (en) | Use of anti-B7H3 antibodies for treating cancer in the central nervous system | |
| BR112015009752A2 (pt) | conjugados de anticorpo/fármaco e métodos de uso | |
| MX2016004822A (es) | Modelos de cancer y metodos asociados. | |
| WO2008094319A3 (en) | Methods and compositions of trail-death receptor agonists/activators | |
| SG10201903112WA (en) | Treatment of cancer using coenzyme q10 combination therapies | |
| CL2011001445A1 (es) | Compuesto 3-(4-cloro-2-fluorobencil)-2-metil-n-(5-metil-1h-pirazol-3-il)-8-(morfolinometil)imidazo[1,2-b]piridazin-6-amina; composicion farmaceutica; y uso en el tratamiento de trastornos mieloproliferantes cronicos y en el tratamiento de glioblastoma, cancer de amama, mieloma multiple, cancer de prostata y leucemias | |
| SA515370134B1 (ar) | تركيبة صيدلانية تحتوي على عامل علاجي قائم على الهيموغلوبين المعدل لعلاج السرطان المستهدف والتصوير التشخيصي | |
| EP3895725A3 (en) | A method for treating tumor by using recombinant interferon with changed spatial configuration | |
| EP3242688A4 (en) | Cox-2-targeting, platinum-containing conjugates and their use in the treatment of tumors and cancers | |
| WO2015181624A3 (en) | Nucleoside derivatives for the treatment of cancer | |
| EA201101651A1 (ru) | Непрерывное введение интегриновых лигандов для лечения рака | |
| MX2015015426A (es) | Metodos de tratamiento de cancer. | |
| MX2020003044A (es) | Dispositivo de administración transdérmica de dextrometorfano. | |
| BR112015005443A2 (pt) | tratamento combinado com fármaco interferente de netrina-1 e fármaco quimioterápico | |
| PH12015502266A1 (en) | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers | |
| AU2013208104A8 (en) | Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof | |
| PH12019501186A1 (en) | Tyrosine derivatives and composition comprising them | |
| MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
| FR2945210B1 (fr) | Combinaison antitumorale comprenant l'ave8062 et le sorafenib |